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CREVIEW CURRENTOPINION Poly(ADP-ribose) polymerase inhibitors in Ewing
sarcomaopyright © Lippincott Will
www.co-oncology.coma,b aBritta Vormoor and Nicola J. CurtinPurpose of review
In 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of
poly(ADP-ribose) polymerase (PARP). This review updates the reader on PARP function, the development of
PARP inhibitors (PARPi) and the evidence for targeting PARP in Ewing sarcoma. It concludes with a
description of ongoing/emerging PARPi clinical trials in patients with Ewing sarcoma.
Recent findings
PARP has a major role in DNA repair, and is a transcription regulator. The oncoprotein in Ewing sarcoma,
EWS-FLI1, is proposed to interact with PARP-1, driving PARP-1 expression, which further promotes
transcriptional activation by EWS-FLI1. Thus, there are two rationales for PARPi in the treatment of Ewing
sarcoma: to disrupt the interaction between EWS-FLI1 and PARP, and for chemo-potentiation or radio-
potentiation. The first clinical trial with a single agent PARPi failed to show significant responses, but
preclinical evidence for combinations of PARPi with chemotherapy or radiotherapy is very promising.
Summary
Despite initial excitement for the potential of PARPi as single agent therapy in Ewing sarcoma, the
emerging preclinical data now strongly support testing PARPi in combination with chemo/radiotherapy
clinically.
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motherapy regimens have led to substantially
increased response and survival rates, the improve-
ment in the survival of patients with primary meta-
static or relapsed Ewing sarcoma remains obstinately
poor. Recent developments in the preclinical setting
suggest that poly(ADP-ribose) polymerase (PARP)
inhibitors (PARPi) may be particularly useful to treat
Ewing sarcoma. This review aims to give some back-
ground to Ewing sarcoma as a disease, the current
treatments and response to therapy. The function of
PARP and the effects of PARPi will be described and
the evidence for a role of PARP in Ewing sarcomawill
be discussed. The reviewwill concludewith a descrip-
tion of the most recent clinical studies of PARPi in
patients with Ewing sarcoma.4300; fax: +44 191 208 4301; e-mail: nicola.curtin@newcastle.ac.uk
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THERAPY
Ewing sarcoma is the secondmost common primary
bone cancer occurring most frequently in the
second decade of life. It occurs predominantly iniams & Wilkins. Unauthocan principally arise from any bone of the skeleton,
and with increasing frequency in older adults also in
extraskeletal sites (soft tissue, kidney, uterus). Pain
in the affected site is usually the first symptom,
followed by swelling and a palpablemass, but patho-
logic fractures also occur at presentation. About
25% of patients present with metastatic disease at
diagnosis, most commonly to lungs, followed by
bone or bone marrow involvement.rized reproduction of this article is prohibited.
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KEY POINTS
 PARP inhibitors in Ewing sarcoma disrupt the interaction
of EWS-FLI1 with PARP-1 and potentiate the DNA
damage caused by certain chemotherapy
(temozolomide, topoisomerase I poisons)
or radiotherapy.
 PARP inhibitors used as single agents in Ewing sarcoma
have shown promising activity in vitro, but none to only
modest activity in xenograft models, and they had
no effect in a phase II clinical trial with continuous
high-dose olaparib.
 PARP inhibitors used in combination with either
temozolomide, irinotecan or radiotherapy have shown
excellent results in vitro and in xenograft tumour
models, and clinical trials results using combination
strategies are eagerly awaited.
PARP inhibitors in Ewing sarcoma Vormoor and CurtinFirst-line treatment is standardized and usually
delivered within phase III clinical trials (e.g. EURO-
E.W.I.N.G.99, subsequent EWING 2012). The
multimodal treatment strategy consists of neo-
adjuvant and adjuvant chemotherapy, local disease
control through surgery, radiotherapy or a combi-
nation of both, and for certain subsets of patients,
high-dose chemotherapy (e.g. busulfan-melphalan)
with autologous stem cell support. These regimes
are currently achieving survival rates of around 70%
for local disease, but for primary metastatic disease,
their predecessor trials achieved only 14–34% [1] or
8–29% [2].
Second-line treatment after relapse or for refrac-
tory disease is currently not standardized, although
there is a proposed study comparing the most com-
monly used regimes (rEEcur study). Chemotherapeu-
tic agents most commonly include combinations of
cyclophosphamide/topotecan or temozolomide/iri-
notecan. Surgery and/or radiotherapymay be used to
attempt local disease control or for metastatic sites.
The overall outcome for patients with relapsed dis-
ease (5 year overall survival of 13%) [3] has remained
unfavourable over the past decades and urgently
requires the development of novel therapeutic
approaches.EWING SARCOMA AND ITS LINK TO
POLY(ADP-RIBOSE) POLYMERASE
Ewing sarcoma is a unique cancer, as it is defined on
a molecular level by a balanced tumour-specific
translocation. In approximately 85% of all tumours,
the EWSR1 gene on chromosome 22 is fused to a
member of the ETS family of transcription factors,
the FLI1 gene on chromosome 11. In the remaining
15% of tumours, the EWS gene is fused to otherCopyright © Lippincott Williams & Wilkins. Unau
1040-8746  2014 Wolters Kluwer Health | Lippincott Williams & Wilkmembers of the ETS transcription factor family,
most commonly the ERG gene on chromosome
21 [4]. The resulting oncoproteins, which serve as
molecular signatures and are viewed as pathogno-
monic for Ewing sarcoma, function as aberrant
oncogenic transcription factors.
Recently, the ETS transcription factors were
shown to interact with PARP-1 in immunoprecipi-
tation experiments published by Brenner et al. [5
&&
],
who were first to report that Ewing sarcoma cell
lines were highly sensitive to PARP inhibition. This
publication was shortly followed by a widely per-
ceived publication by Garnett et al. [6
&&
] from
the Cancer Genome Project, who identified the
EWS-FLI1 translocation as a biomarker for PARPi
sensitivity.POLY(ADP-RIBOSE) POLYMERASE AND
THE THERAPEUTIC UTILITY OF ITS
INHIBITORS
There is a superfamily of 17 PARP enzymes of which
PARP-1 is the founding member andmost abundant
[7]. The best characterized role for PARP-1 is not only
in the repair of DNA breaks but also the regulation of
transcription by, for example, modulating chroma-
tin structure, changing DNA methylation patterns
and as a co-regulator of transcription factors [8].
PARP-2 has a somewhat overlapping role in DNA
single-strand break repair and PARP-3 co-operates
with PARP-1 in the repair of DNA double-strand
breaks [9]. PARP-1 is activated by binding to DNA
breaks to catalyze the formation of long homopol-
ymers of ADP ribose (PAR) from NADþ that recruit
the repairmachinery and loosen chromatin to facili-
tate repair. PARPi were developed for cancer therapy
based on the simple premise that cancer therapy
damages DNA, and DNA repair compromises the
therapeutic efficacy; therefore, inhibiting DNA
repair should increase the efficacy. Inhibitor devel-
opment started with academic groups in the late
1970s and early 1980s and for a long time, 3-amino-
benzamide (3AB) was the only compound available.
A decade later, inhibitors more than 100 more
potent than 3AB were developed. Because of the
similarity of the catalytic domain, most PARPi are
at least as active against PARP-2 as PARP-1. These
second-generation inhibitors confirmed data
obtained using 3AB, that PARPi inhibit the repair
of DNA damage and enhance the cytotoxicity of
DNA methylating agents (e.g. temozolomide), top-
oisomerase I poisons (e.g., topotecan) and ionizing
radiation with some cell-specific potentiation of
cisplatin [10]. Subsequent expansion of the investi-
gations by academic and industrial groups identified
ever more potent inhibitors that, as well as beingthorized reproduction of this article is prohibited.
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CSarcomashighly potent (1000more potent than 3AB), had
improved pharmacological properties that allowed
studies in mice bearing a variety of xenografted
tumours. These xenograft studies, which were
largely representative of not only adult human
tumours, particularly colon carcinoma [11],
brain tumours and melanomas [12], but also for
paediatric tumours, such as medulloblastoma [13]
and neuroblastoma [14], confirmed the efficacy
with temozolomide, irinotecan and irradiation.
The first clinical trial of a PARPi in cancer patients
was in 2003, in which rucaparib (AG014699) was
given in combination with temozolomide [15].
More recently, PARPi have been shown to be
synthetically lethal in cells lacking another DNA
repair pathway: homologous recombination repair
(HRR). Synthetic lethality explains the phenomenon
in which blocking two complementary enzymes or
pathways together results in cell death, but blocking
either alone does not compromise viability. The
tumour suppressors BRCA1 and BRCA2 play import-
ant roles in HRR and mutations in these genes are
associated with breast, ovarian and some other can-
cers. As only tumours are HRR-defective and normal
tissues retain HRR function (except in cases of rare
genetic diseases), this represents a nontoxic, tumour-
selective therapeutic manoeuvre. These exciting
developments have led to an expansion in the field
and there are currently five PARPi in advanced pre-
registration clinical trials, mostly in BRCA/HRR-
defective breast or ovarian cancer [16].RATIONALE FOR POLY(ADP-RIBOSE)
POLYMERASE INHIBITOR THERAPY IN
EWING SARCOMA
There are two potential justifications for considering
PARPi therapy in Ewing sarcoma: first, its potential
as a single agent based on the association of PARP-1
with ETS transcription factors and secondly as a
chemotherapy/radiotherapy potentiating agent in
combination with either ionizing radiation, temo-
zolomide or topotecan, all used for the treatment of
relapsed Ewing sarcoma.POLY(ADP-RIBOSE) POLYMERASE
INHIBITORS AS SINGLE AGENTS
The first publication to suggest that PARPi may be
active as single agents in Ewing sarcoma came from
the group at the University of Michigan, who were
first to publish on the interaction between EWS-FLI1
and PARP-1, and the sensitivity of Ewing sarcoma
cells to PARP inhibition.
The group had previously shown that the
protein product of TMPRSS2-ERG, an ETS fusionopyright © Lippincott Williams & Wilkins. Unautho
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that PARPi inhibited ETS-positive prostate xenograft
growth [17]. Based on these findings, they investi-
gated ETS fusion genes in Ewing sarcoma, EWS-FLI1
or EWS-ERG. Immunoprecipitation experiments
using either FLI1 or ERG antibodies, which recog-
nized the respective fusion proteins, pulled down
PARP-1 in a DNA-independent manner. Clonogenic
assays in soft agar demonstrated that cells overex-
pressing EWS-FLI1 or EWS-ERG were sensitive to the
PARPi olaparib. Ewing sarcoma cell lines, including
those from heavily pretreated patients, were simi-
larly highly sensitive to continuous single agent
olaparib exposure, whereas control cell lines from
rhabdomyosarcomas or osteosarcomas showed
unhindered growth. These findings were confirmed
in a mouse xenograft model, in which single agent
olaparib delayed subcutaneous Ewing sarcoma (RD-
ES) tumour growth to a comparable extent as single
agent temozolomide. They also demonstrated that
the ETS fusion protein was associated with increased
levels of DNAdamage,measured by gH2A.X foci and
COMET assays, which could be potentiated by PARP
inhibition. Interestingly, in cell invasion assays,
siRNAs against PARP-1 and EWS reduced cell inva-
sion, but knock-down of other key DNA repair
enzymes (XRCC1; base excision repair; XRCC3;
HRR and XRCC4; nonhomologous end joining)
had no effect. The group therefore concluded that
PARP-1 has a DNA repair-independent role in Ewing
sarcoma cell migration. Finally, they demonstrated
that EWS-FLI1 maintains PARP-1 mRNA expression,
as knockdownof EWS-FLI1 decreased PARP-1 protein
expression and promotor activity. In conclusion,
they postulated a EWS-FLI1:PARP-1-positive feed-
back loop in transcriptional activation, together
with the potentiation of DNA damage by PARP-1
inhibition as the two mechanisms contributing to
the PARPi sensitivity of Ewing sarcoma (Fig. 1).
Shortly afterwards, the large collaboration of the
Cancer Genome Project [6
&&
] published the screen-
ing results of more than 600 human cancer cell lines
against 130 different drugs under clinical and pre-
clinical investigation, in which the particular sensi-
tivity of cells harbouring the EWS-FLI1 oncogene to
PARPi was revealed as an unexpected finding. In cell
viability and clonogenic assys, cell lines carrying
the EWS-FLI1 translocation were significantly more
sensitive to two PARPi (olaparib and rucaparib),
than their EWS-FLI1-negative controls. The consor-
tium also determined whether the EWS-FLI1 fusion
gene was essential for the sensitivity to PARPi, or
whether it was intrinsic to the mesenchymal pre-
cursor cells from which Ewing sarcoma originates.
They therefore compared the PARPi sensitivity of
mouse mesenchymal cells transformed with eitherrized reproduction of this article is prohibited.
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FIGURE 1. Proposed model for interaction of PARP-1 and
EWS fusion genes and the potential role for PARPi. EWS
fusion gene (exemplified by EWS FLI1) promotes PARP-1
expression, which in turn promotes EWS FLI1 transcriptional
activation, creating a positive feedback loop that promotes
EWS FLI1-driven malignancy. EWS FLI1 expression results in
higher levels of DNA damage that requires PARP-1 for
repair. Temozolomide, irinotecan/topotecan and ionizing
radiation all cause DNA damage that is repaired in a PARP-
dependent manner. PARPi may have single-agent activity in
Ewing sarcoma by blocking the positive feedback loop
thereby removing the oncogenic driving force, and inhibiting
the repair of EWS FLI1-generated DNA damage. PARPi
increase the efficacy of temozolomide, irinotecan/topotecan
and ionizing radiation by inhibiting repair of the DNA
damage they cause. PARP, poly(ADP-ribose) polymerase;
PARPi, poly(ADP-ribose) polymerase inhibitor.
PARP inhibitors in Ewing sarcoma Vormoor and CurtinEWS-FLI1 or the liposarcoma-associated transloca-
tion FUS-CHOP. Cells transformed with EWS-FLI1
were as sensitive as human Ewing sarcoma cell
lines to olaparib, whereas FUS-CHOP transformed
cells were resistant, and transient depletion of
EWS-FLI1 in Ewing sarcoma cells led to reduced
PARPi sensitivity. They concluded therefore that
the sensitivity of Ewing sarcoma cells to PARP
inhibition might be caused by EWS-FLI1 transcrip-
tional activity.
Despite these promising preclinical results for
single agent PARPi, this did not translate into the
successful application of single agent PARPi in xen-
ograft models. The Paediatric Preclinical Testing
Programme (PPTP) evaluated the PARPi BMN 673
in a range of different xenograft mouse models, and
all tested Ewing sarcoma models (n¼5 cell lines)
showed progressive disease when treated with single
agent BMN 673 continuously over 28 days [18].
Another group tested single agent olaparib in a
similar Ewing sarcoma xenograftmodel to theMich-
igan group (RD-ES), and found that olaparib did not
improve survival [19
&&
].Copyright © Lippincott Williams & Wilkins. Unau
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INHIBITORS AS CHEMOTHERAPY AND
RADIOTHERAPY-POTENTIATING AGENTS
The DNA damage caused by the two groups of
chemotherapeutic agents most commonly used in
second-line treatment of Ewing sarcoma (topoiso-
merase I poisons, i.e. topotecan, irinotecan, and
methylating agents, i.e. temozolomide), and also
radiotherapy, can be potentiated by PARPi, as
already described in a previous paragraph (PARP
and the therapeutic utility of its inhibitors). For
Ewing sarcoma, the potentiating effects of olaparib
in combination with temozolomide were first
published by the Michigan group [5
&&
] who demon-
strated that in mice bearing Ewing sarcoma xeno-
grafts concomitant treatment with temozolomide
and olaparib caused tumour regressions and sus-
tained complete responses. Our own group demon-
strated that Ewing sarcoma cells can be sensitized
in vitro to temozolomide, and to a lesser extent to
ionizing radiation, by co-treatment with the PARPi
inhibitor rucaparib (AG014699) [20
&
]. In colony
formation survival assays, 0.4mmol/l of rucaparib
caused a 15–28 fold sensitization of temozolomide
and a 1.5-fold radiosensitization in CADO-Ewing
sarcoma and TC-71 Ewing sarcoma cells. In-vitro
data for the combinations of irinotecan or its active
metabolite SN-38 with olaparib have demonstrated
strong synergy for both combinations in Ewing
sarcoma cell lines (RD-ES and TC-71), with a com-
bination index of approximately 0.35 and 0.25
[19
&&
].
The effect of PARPi treatment in combination
with temozolomide and irinotecan in Ewing sar-
coma tumour graft models has also been published
for the PARPi niraparib [21
&&
] and BMN 673 [18]. The
Wilcoxon group presented impressive in-vivo evi-
dence for combining either irinotecan or temozolo-
mide with niraparib, with complete regression of
patient-derived Ewing sarcoma tumours in all tested
mice using two different schedules: full-dose temo-
zolomide (daily for 5 days) or irinotecan (once
weekly) combined with niriparib (daily for 5 days),
or half-dose temozolomide or irinotecan and con-
tinuous niriparib. Interestingly, although toxicity
was observed with the former schedule, there was
none with the latter and continuous niriparib alone
slowed tumour growth. The PPTP group also pre-
sented impressive data on the PARPi BMN 673,
which potentiates the activity of temozolomide
in vitro, exceeding 50-fold for some Ewing sarcoma
cell lines. They also tested 10 different Ewing sar-
coma xenograft models, and five of 10 showed a
maintained complete response when treated with a
combination of BMN 673 and low-dose temozolo-
mide.thorized reproduction of this article is prohibited.
ins www.co-oncology.com 431
CTable 1. Overview of clinical trials for Ewing sarcoma patients utilizing PARP inhibitors
PARP inhibitor Company Monotherapy
Combination
treatments
Age of eligible
patients Trial status Reference
Olaparib Astra Zeneca Phase II trial
NCT01583543
>18 years Closed [23&&]
Phase I with
temozolomide
NCT01858168
>18 years Open
With radiotherapy In preparation [22&&]
BMN 673 BioMarin Phase I trial
NCT01286987
>18 years, not
exclusively in
Ewing patients
Open [18,24]
Niraparib Tesaro Phase I with
temozolomide
NCT02044120
>13 years To open March
2014
[21&&]
E7449 Esai
Other PARP inhibitors in Phase II/III clinical trials not currently tested in Ewing sarcoma
Rucaparib Clovis
Veliparib Abott
CEP-9722 Cephalon
PARP, poly(ADP-ribose) polymerase.
SarcomasFurther preclinical evidence that PARPi poten-
tiate the effects of ionizing radiation in Ewing
sarcoma has recently been published [22
&&
]. In this
study, Ewing sarcoma cells, but not non-Ewing
sarcoma cells, were sensitized to radiotherapy by
olaparib, and this also translated to a xenograft
mouse model, in which olaparib in combination
with a single dose of ionizing radiation substantially
delayed tumour growth. These findings open new
potential treatment strategies for patients with
unresectable Ewing sarcoma tumours, to either
improve the efficacy of radiation, or to potentially
achieve the same efficacy with reduced radiation
doses. A first clinical trial to combine radiation with
PARP inhibition is currently in preparation.POLY(ADP-RIBOSE) POLYMERASE
INHIBITORS IN CLINICAL TRIALS
These encouraging preclinical results, both in vitro
and in vivo, have led to early clinical trials with
different PARPi in patients with Ewing sarcoma
(overview in Table 1) [18,21
&&
–23
&&
,24]. In a phase
II pilot study with olaparib (NCT01583543), 12
patients with advanced Ewing sarcoma progressing
after chemotherapy were treated with 400mg of
olaparib twice daily, and response was assessed by
computed tomography or MRI at regular intervals.
There was tolerable grade 3 toxicity in two of 12
patients, but unfortunately no partial or complete
responses could be observed. Best responses were
four patients with stable disease but eight patients
had progressive disease and further enrolment was
stopped [23
&&
]. This somewhat disappointing resultopyright © Lippincott Williams & Wilkins. Unautho
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nation trial of olaparib (50–200-mg twice daily)
and temozolomide (50–75mg/m2), begun in July
2013 (NCT01858168), in patients with metastatic
and/or unresectable, relapsed or refractory Ewing
sarcoma. Another trial is testing the PARPi BMN
673 as a single agent in a range of advanced or
recurrent solid tumours, including patients with
Ewing sarcoma (NCT01286987), but so far without
any objective responses in nine of 14 patients, the
remaining five were too early to be evaluated [24].
All ongoing trials so far are limited to adult patients.
Apart from these three trials, there are several com-
bination studies currently being designed or in prep-
aration. All results are eagerly awaited, so that also
the paediatric/adolescent age group can at some
point hopefully benefit from combinations of PARPi
with chemotherapy or radiotherapy.CONCLUSION
Since the two groundbreaking publications in 2012,
showing Ewing sarcoma cells to be particularly sen-
sitive to PARP inhibition, PARPi have emerged as a
new class of drugs to treat Ewing sarcoma. PARPi
monotherapy in xenograft models showed some
moderate effects, but in a first clinical trial in patients
with relapsed Ewing sarcoma, monotherapy did not
translate into sufficient responses, despite being well
tolerated. However, combinations of PARPi with
temozolomide, topoisomerase I poisons and/or
radiotherapy have shown excellent in-vivo results
and are therefore currently the most favoured
strategy for upcoming clinical trials.rized reproduction of this article is prohibited.
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